|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Sekar_Kathiresan
|
|
gptkbp:clinicalTrialPhase
|
VERVE-101 for heterozygous familial hypercholesterolemia
|
|
gptkbp:collaboratesWith
|
gptkb:Bayer
gptkb:Vertex_Pharmaceuticals
gptkb:Beam_Therapeutics
|
|
gptkbp:focusesOn
|
gptkb:cardiovascular_disease
gene editing
|
|
gptkbp:foundedYear
|
2018
|
|
gptkbp:founder
|
gptkb:Kiran_Musunuru
gptkb:Sekar_Kathiresan
|
|
gptkbp:hasCompany
|
true
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Verve Therapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:investor
|
gptkb:Casdin_Capital
gptkb:F-Prime_Capital
gptkb:GV_(Google_Ventures)
gptkb:ARCH_Venture_Partners
|
|
gptkbp:listedOn
|
gptkb:NASDAQ
|
|
gptkbp:mission
|
to create a world free from cardiovascular disease
|
|
gptkbp:notableProduct
|
gptkb:VERVE-101
|
|
gptkbp:numberOfEmployees
|
100-200 (as of 2023)
|
|
gptkbp:stockSymbol
|
gptkb:VERV
|
|
gptkbp:technology
|
base editing
|
|
gptkbp:therapeuticArea
|
cardiometabolic diseases
|
|
gptkbp:website
|
https://www.vervetx.com/
|
|
gptkbp:bfsParent
|
gptkb:Google_Ventures
gptkb:Beam_Therapeutics
|
|
gptkbp:bfsLayer
|
5
|